Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of Phase Ⅰb/II to Evaluate the Safety, Efficacy and Pharmacokinetic Characteristics of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis

NCT05525715 is registered in ClinicalTrials.gov with E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. as lead sponsor.

NCT NCT05525715
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05525715 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of Phase Ⅰb/II to Evaluate the Safety, Efficacy and Pharmacokinetic Characteristics of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis
Lead sponsor
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
Phase
Phase 1/2
Overall status
Unknown status
Start date
October 31, 2022
Completion date
December 31, 2025
Enrollment
260 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis